Back to top
more

Kiniksa Pharmaceuticals (KNSA)

(Real Time Quote from BATS)

$17.91 USD

17.91
11,376

+0.30 (1.70%)

Updated Apr 26, 2024 10:22 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for KNSA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Kiniksa Pharmaceuticals, Ltd. [KNSA]

Reports for Purchase

Showing records 1 - 20 ( 108 total )

Company: Kiniksa Pharmaceuticals, Ltd.

Industry: Medical - Biomedical and Genetics

Record: 1

04/02/2024

Company Report

Pages: 7

Abripubart Seeking Sjogren’s

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Kiniksa Pharmaceuticals, Ltd.

Industry: Medical - Biomedical and Genetics

Record: 2

02/28/2024

Company Report

Pages: 6

Arcalyst Springing Forward; Abiprubart''s on the Clock

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Kiniksa Pharmaceuticals, Ltd.

Industry: Medical - Biomedical and Genetics

Record: 3

02/01/2024

Industry Report

Pages: 20

Biotechnology-Monthly Check-Up - February 2024

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 50.00

Research Provided by a Third Party

Company: Kiniksa Pharmaceuticals, Ltd.

Industry: Medical - Biomedical and Genetics

Record: 4

01/04/2024

Company Report

Pages: 6

Primed for Another Strong Year in RP; Waiting to See the River in RA

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Kiniksa Pharmaceuticals, Ltd.

Industry: Medical - Biomedical and Genetics

Record: 5

01/02/2024

Company Report

Pages: 6

Ruminating on KPL-404’s Prospects in Rheumatoid Arthritis

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Kiniksa Pharmaceuticals, Ltd.

Industry: Medical - Biomedical and Genetics

Record: 6

11/22/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for KNSA 112123

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Kiniksa Pharmaceuticals, Ltd.

Industry: Medical - Biomedical and Genetics

Record: 7

10/31/2023

Company Report

Pages: 5

Arcalyst Sees and Raises to the Top End; Looking For ‘404 in Q1

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 5.00

Research Provided by a Third Party

Company: Kiniksa Pharmaceuticals, Ltd.

Industry: Medical - Biomedical and Genetics

Record: 8

10/27/2023

Industry Report

Pages: 8

The Week Ahead in Life Sciences

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Kiniksa Pharmaceuticals, Ltd.

Industry: Medical - Biomedical and Genetics

Record: 9

07/25/2023

Company Report

Pages: 5

Arcalyst Movin'' on Up and to the Right

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 5.00

Research Provided by a Third Party

Company: Kiniksa Pharmaceuticals, Ltd.

Industry: Medical - Biomedical and Genetics

Record: 10

05/02/2023

Company Report

Pages: 5

Bigger, Faster, Better, More! Arcalyst Strong Q1; 2023 Guidance Increased

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 5.00

Research Provided by a Third Party

Company: Kiniksa Pharmaceuticals, Ltd.

Industry: Medical - Biomedical and Genetics

Record: 11

03/01/2023

Daily Note

Pages: 17

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Kiniksa Pharmaceuticals, Ltd.

Industry: Medical - Biomedical and Genetics

Record: 12

02/28/2023

Company Report

Pages: 5

Keep on Keepin'' on Kiniksa

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 5.00

Research Provided by a Third Party

Company: Kiniksa Pharmaceuticals, Ltd.

Industry: Medical - Biomedical and Genetics

Record: 13

01/10/2023

Daily Note

Pages: 12

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Kiniksa Pharmaceuticals, Ltd.

Industry: Medical - Biomedical and Genetics

Record: 14

01/10/2023

Company Report

Pages: 5

A Strong Close to 2022 for Arcalyst, Continued Growth Ahead

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 5.00

Research Provided by a Third Party

Company: Kiniksa Pharmaceuticals, Ltd.

Industry: Medical - Biomedical and Genetics

Record: 15

11/01/2022

Company Report

Pages: 6

Arcalyst Keeping Pace

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Kiniksa Pharmaceuticals, Ltd.

Industry: Medical - Biomedical and Genetics

Record: 16

08/03/2022

Company Report

Pages: 6

Turbocharging Arcalyst Acceleration

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Kiniksa Pharmaceuticals, Ltd.

Industry: Medical - Biomedical and Genetics

Record: 17

05/03/2022

Company Report

Pages: 5

ARCALYST Starts the Year With a Bang

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 5.00

Research Provided by a Third Party

Company: Kiniksa Pharmaceuticals, Ltd.

Industry: Medical - Biomedical and Genetics

Record: 18

02/22/2022

Industry Report

Pages: 11

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Kiniksa Pharmaceuticals, Ltd.

Industry: Medical - Biomedical and Genetics

Record: 19

02/22/2022

Company Report

Pages: 6

ARCALYST Scores a Triple and Looks to Overseas Expansion

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Kiniksa Pharmaceuticals, Ltd.

Industry: Medical - Biomedical and Genetics

Record: 20

01/10/2022

Company Report

Pages: 5

Highlights Pipeline Progress While We Await ARCALYST Updates

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 5.00

Research Provided by a Third Party